BIMO Considering Random Sampling Of Clinical Investigator Audits
This article was originally published in The Gray Sheet
Executive Summary
FDA's Bioresearch Monitoring division is considering the random sampling of clinical investigator inspections in the future, according to staffers at the Center for Devices and Radiological Health.